骨髓增殖性疾病患者JAK2基因V617F突变频率、磷酸化JAKSTAT蛋白表达水平及临床意义 万方数据
Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorder 2012;323(1-2):178-182.Janus kinase ( JAK ) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative ... Tanima,De,...
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
in JAK2V617F-positive 32D cells as well as patient samples (peripheral blood mononuclear cells and CD34+ hematopoietic stem cells) compared to their CALR-mutated counterparts, and higher IFNa doses were needed to achieve the same IFNa response in CALR− as in JAK2V617F-mutant 32D cells. ...
Ruxolitinib is not specific for the JAK2V617F mutation, and its efficacy in MF is mainly due to the attenuation of the constitutive activation of the JAK/STAT pathway and myelosuppression.398 For ruxolitinib-resistant or ruxolitinib-intolerant MF patients, another JAK2-selective inhibitor fedratinib...
It also regulates the signaling of TPO-R and EPO-R, and it is detected in both JAK2 V617F-positive and -negative patients.10 Increased LNK deficiency increases the oncogenic ability of JAK2 to expand myeloid progenitors in vitro and in vivo.41 Mutation in the Janus kinase 2 gene and ...
Results: The total leukocytes count and the presence of blast cells were compared in between JAK2 positive and JAK2 negative patients. Patient's positive for JAK2 mutation had higher total leucocytes counts (a mean of 20.4 × 10 9/l) and less circulating blasts 7/35 (36.8%) as compared to...
Fig.2JAK2V617F mutation by DNA sequence analysis.a mutation type allele,b Wild type allele Fig.3FISH using the LSI BCR–ABL ES probe,positive cells showed 1Y,2R,1G fusion signals transcript at a high level(ratio BCR–ABL/ABL:161%). The presence of the t(9;22)was confirmed by...
et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790 (2005). CAS PubMed Google Scholar Jones, A. V. et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106, 2162–2168 (2005)...
223 JAK2V617F results in constitutive tyrosine phosphorylation activity and is the most prevalent gain-of-function alteration in the majority of MPNs.61,224,225,226 Experiments with Pf4-Cre transgenic mice indicated that activated JAK-STAT signaling in megakaryocytes with the JAK2V617F mutation ...